Metabolic differences of current thienopyridine antiplatelet agents

Bibliography

• Abbracchio MP, Boeynaems J-M, Barnard EA, Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 2003;24(2):52-5
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Burnstock G, Boeynaems J-M, International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006;58(3):281-341
   PubMed Web of Science ®Google Scholar
• Hollopeter G, Jantzen HM, Vincent D, Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409(6817):202-7
   PubMed Web of Science ®Google Scholar
• Foster CJ, Prosser DM, Agans JM, Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107(12):1591-8
   PubMed Web of Science ®Google Scholar
• Porto I, Giubilato S, De Maria GL, Platelet P2Y12 receptor inhibition by thienopyridines: status and future. Expert Opin Investig Drugs 2009;18(9):1317-32
   PubMed Web of Science ®Google Scholar
• FDA Guidance compliance regulatory information. Guidance on ticlopidine hydrochloride active ingredient: ticlopidine hydrochloride form/route: tablet/oral recommended studies. Available from: http://google2.fda.gov/search?q=cache:BVMknFBlxIAJ:www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM090618.pdf+ticlopidine&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&ie=UTF-8&access=p&oe=ISO-8859-1 [Accessed January 16, 2012]
   Google Scholar
• Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 1994;26(5):347-55
   PubMed Web of Science ®Google Scholar
• Knudsen JB, Bastain W, Sefton CM, Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992;22(5):579-89
   PubMed Web of Science ®Google Scholar
• Yoneda K, Iwamura R, Kishi H, Identification of the active metabolite of ticlopidine from rat in vitro metabolites. Br J Pharmacol 2004;142(3):551-7
   PubMed Web of Science ®Google Scholar
• Ha-Duong NT, Dijols S, Macherey AC, Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001;40:12112-22
   PubMed Web of Science ®Google Scholar
• Richter T, Mürdter TE, Heinkele G, Potent mechanismbased inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004;308:189-97
   PubMed Web of Science ®Google Scholar
• Dalvie DK, O’Connell TN. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases. Drug Metab Dispos 2004;32:49-57
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50(2):126-42
   PubMed Web of Science ®Google Scholar
• Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 1997;62(5):572-7
   PubMed Web of Science ®Google Scholar
• Ha-Duong NT, Dijols S, Macherey AC, Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001;40(40):12112-22
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishiya Y, Kurihara A, Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab. Pharmacokinet 2008;23(6):412-20
   PubMed Web of Science ®Google Scholar
• Buur T, Larsson R, Berglund U, Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharmacol 1997;37(2):108-15
   PubMed Web of Science ®Google Scholar
• Hirata K, Takagi H, Yamamoto M, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case control study. Pharmacogenomics J 2007;8(1):29-33
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Koch W, Mehilli J, Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood 2000;95(11):3297-301
   PubMed Web of Science ®Google Scholar
• Walsky RL, Astuccio AV, Obach RS. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 2006;46(12):1426-38
   PubMed Web of Science ®Google Scholar
• Sanofi-aventis. PLAVIX® (clopidogrel bisulfate) tablets Prescribing Information. Available from: http://products.sanofi.us/PLAVIX/PLAVIX.html [Accessed 16 January 2012]
   Google Scholar
• Kim B-H, Kim K-P, Lim KS, Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010;32(2):380-90
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999;281(9):806-10
   PubMed Web of Science ®Google Scholar
• Cosmi B, Rubboli A, Castelvetri C, Milandri M. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001(4):CD002133
   Google Scholar
• Takakusa H, Masumoto H, Mitsuru A, Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes. Drug Metab Dispos 2008;36(5):816-23
   PubMed Web of Science ®Google Scholar
• Ruan Q, Zhu M. Investigation of bioactivation of ticlopidine using linear ion trap/orbitrap mass spectrometry and an improved mass defect filtering technique. Chem Res Toxicol 2010;23(5):909-17
   PubMed Web of Science ®Google Scholar
• Gachet C, Stierlé A, Cazenave JP, The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990;40(2):229-38
   PubMed Web of Science ®Google Scholar
• Savi P, Nurden P, Nurden AT, Clopidogrel: a review of its mechanism of action. Platelets 1998;9(3-4):251-5
   PubMed Web of Science ®Google Scholar
• Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin. Thromb. Hemost 1999;25(Suppl 2):25–28
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Taubert D, Pogatsa-Murray G, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112(19):2946-50
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sideris G, Meuleman C, A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol 2006;48(5):931-8
   PubMed Web of Science ®Google Scholar
• Payne CD, Li YG, Small DS, Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50(5):555-62
   PubMed Web of Science ®Google Scholar
• Müller I, Seyfarth M, Rüdiger S, Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85(1):92-3
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84(5):891-6
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38(1):92-9
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schömig E, van Werkum JW, Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17(1):110-16
   PubMed Web of Science ®Google Scholar
• Paré G, Ross S, Mehta SR, Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the unstable angina to prevent recurrent events trial and the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Circ Cardiovasc Genet 2012;5(2):250-6
   PubMed Web of Science ®Google Scholar
• Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost 1999;25(Suppl 2):29-33
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics 2010;20(7):463-5
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006;319:1467-76
   PubMed Web of Science ®Google Scholar
• Hulot J-S, Bura A, Villard E, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108(7):2244-7
   PubMed Web of Science ®Google Scholar
• Hagihara K, Kazui M, Kurihara A, A Possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009;37(11):2145-52
   PubMed Web of Science ®Google Scholar
• Yang D, Pearce RE, Wang X, Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 2009;77(2):238-47
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Capodanno D, Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010;55(11):1139-46
   PubMed Web of Science ®Google Scholar
• Smith SMG, Judge HM, Peters G, Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006;17(4):250-8
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-75
   PubMed Web of Science ®Google Scholar
• Suh J-W, Koo B-K, Zhang S-Y, Increased risk of atherothrombotic events associated with cytochrome p450 3a5 polymorphism in patients taking clopidogrel. CMAJ 2006;174(12):1715-22
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360(4):354-62
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Public health advisory: updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm [Accessed 1 June 2012]
   Google Scholar
• Dunn S, Macaulay T, Brennan D, Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118:S_815
   Google Scholar
• Frelinger AL, Lee RD, Mulford DJ, A randomized open-label 2-period crossover design study to assess the steady-state effects of dexlansoprazole lansoprazole esomeprazole or omeprazole on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects. J Am Coll Cardiol 2011;57(14):E1098
   Web of Science ®Google Scholar
• Medwatch the fda safety information and adverse event reporting program. Safety alerts for human medical products - clopidogrel (marketed as Plavix) and omeprazole (marketed as Prilosec) - drug interaction. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm [Accessed 24 February 2012]
   Google Scholar
• Farid NA, Payne CD, Small DS, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81(5):735-41
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005;77(6):553-9
   PubMed Web of Science ®Google Scholar
• Richter T, Mürdter TE, Heinkele G, Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004;308(1):189-97
   PubMed Web of Science ®Google Scholar
• Aruna D, Naidu MUR. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007;63(3):333-8
   PubMed Web of Science ®Google Scholar
• Zakarija A, Bandarenko N, Pandey DK, Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the food and drug administration. Stroke 2004;35(2):533-7
   PubMed Web of Science ®Google Scholar
• Oppedijk B, Odekerken DAM, van der Wildt JJ, Melissant CF. Rapid oral desensitisation procedure in clopidogrel hypersensitivity. Neth Heart J 2008;16(1):21-3
   PubMed Web of Science ®Google Scholar
• Williams ET, Jones KO, Ponsler GD, The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008;36(7):1227-32
   PubMed Web of Science ®Google Scholar
• Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy 2009;29(9):1089-102
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153(1):66.e9-16
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S, Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29(1):21-30
   PubMed Web of Science ®Google Scholar
• Eli Lilly. Acute Coronary syndrome - percutaneous coronary intervention - effientHCP.com (prasugrel) tablets. Available from: http://www.effienthcp.com/Pages/index.aspx?WT.srch=1&WT.mc_id=EffHSACPEfL2056-75508 [Accessed 26 January 2012]
   Google Scholar
• Lazar LD, Lincoff AM. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk. Cleve Clin J Med 2009;76(12):707-14
   PubMed Web of Science ®Google Scholar
• Rehmel JLF, Eckstein JA, Farid NA, Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. drug metab. Dispos 2006;34(4):600-7
   PubMed Web of Science ®Google Scholar
• Small DS, Wrishko RE, Ernest CS II, Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end‐stage renal disease. J Clin Pharm Ther 2009;34(5):585-94
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376(9749):1312-19
   PubMed Web of Science ®Google Scholar
• Varenhorst C, James S, Erlinge D, Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur. Heart J 2009;30(14):1744-52
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost 2007;5(12):2429-36
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010;49(12):777-98
   PubMed Web of Science ®Google Scholar
• Farid NA, Jakubowski JA, Payne CD, Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009;25(8):1821-9
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374(9694):989-97
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Li YG, Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008;24(8):2251-7
   PubMed Web of Science ®Google Scholar
• Farid NA, Small DS, Payne CD, Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008;28(12):1483-94
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-31
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD, 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Circulation 2011;123(18):2022-60
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: Postmarket Drug Safety Information for Patients and Providers. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforpatientsandProviders/ucm203888.htm [Accessed 25 February 2012]
   Google Scholar
• Small DS, Payne CD, Kothare P, Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 2010;32(2):365-79
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008;118(16):1626–36
   PubMed Web of Science ®Google Scholar
• Makkar K, Wilensky RL, Julien MB, Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother 2006;40(6):1204-7
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEJM 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009;7(10):1195-201
   PubMedGoogle Scholar
• Chackalamannil S, Wang Y, Greenlee WJ, Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51(11):3061-4
   PubMed Web of Science ®Google Scholar
• Wahi R, Rao G, Thethi I, Pathak L. Prevalence of free methyl chloride as an impurity in generic clopidogrel preparations. safety implications in cardiovascular patients. Circulation 2010;122:A17290
   Google Scholar
• Messmore HL, Jeske WP, Wehrmacher W, Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am 2005;19(1):87-117; vi
   PubMed Web of Science ®Google Scholar
• Nonhemostatic adverse effects of anticoagulants and antiplatelet agents. Semin Thromb Hemost 2012;38(8):884-92
   PubMed Web of Science ®Google Scholar